Medis and PAION Have Signed Commercialization Agreement for Three Innovative Hospital Therapies

Medis and PAION Have Signed Commercialization Agreement for Three Innovative Hospital Therapies

Medis has signed a commercialization agreement with PAION, a specialty pharmaceutical company in the field of anaesthesia and critical care. Under the agreement, Medis will be an exclusive partner for the commercialization of three innovative products – angiotensin II, eravacycline and remimazolam – in 9 different markets across the CEE region.

Medis' Hospital Care business unit will be responsible for supply, distribution and marketing and sales of angiotensin II, eravacycline and remimazolam in Bulgaria, Croatia, the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Slovakia and Slovenia.

Angiotensin II is anintravenous infusion indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.

Eravacycline is the first fully synthetic fluorocycline antibiotic, indicated for the treatment of complicated intra-abdominal infections in adults. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Remimazolam is an intravenous, ultra-short-acting sedative used for procedural sedation and general anaesthesia. It is approved for the use in adult patients in the U.S., the EU/EEA/UK, China and South Korea for procedural sedation and in Japan and South Korea for general anaesthesia. It is effective in sedating patients undergoing procedures such as colonoscopies or bronchoscopies. Remimazolam has a quick onset of action and sedative effects disappear shortly after the procedure, allowing shorter times for the procedures compared to other benzodiazepines.

With this agreement we have enabled patients in the CEE region access to innovative hospital therapies. Angiotensin II and eravacycline will provide new efficient treatment possibilities for critically ill patients, while remimazolam, with its rapid onset, brings safe and effective procedural sedation options,

said Albina Pečarič, Managing Director Medis Hospital Care.

For Medis, this partnership represents further strengthening in the therapeutic area of anaesthesia and critical care and we sincerely look forward to working with PAION.

Headquartered in Germany, PAION is a publicly listed specialty pharmaceutical company with a portfolio of innovative medicines to be used in hospital-based sedation, anaesthesia and critical care services.

Related news